SCHEMBL1848638

SCHEMBL1848638

Cc1nc2cc(-c3ccc(NC(=O)OC(C)(C)C)cc3)ccc2s1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.52
MAP4K4 O95819 1/20 0.52
CYP17A1 P05093 3/20 0.49
PSMB8 P28062 1/20 0.47
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LDHA P00338 1/20 0.45
SREBF2 Q12772 1/20 0.45
ROCK2 O75116 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
P2RX3 P56373 2/20 0.44
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14554346 0.90 TRPV1 (0.62) TRPV1RAB9ANPC1CASP3SENP7
SCHEMBL14079744 0.83 LDHA (0.67) RAB9ANPC1SMN1; SMN2LDHAKMT2A
SCHEMBL3306182 0.80 MAP4K4 (0.56) MAP4K4CYP17A1PSMB8RAB9ANPC1
SCHEMBL16307608 0.78 MAP4K4 (0.59) MAP4K4CYP17A1PSMB8RAB9ANPC1
SCHEMBL20865536 0.77 CYP17A1 (0.68) MAP4K4CYP17A1PSMB8SMN1; SMN2
SCHEMBL1853997 0.75 APP (0.55) TRPV1RAB9ANPC1CASP3SENP7
SCHEMBL10165143 0.75 DYRK1A (0.54) TRPV1RAB9ANPC1SMN1; SMN2P2RX3
SCHEMBL12393106 0.75 TP53 (0.72) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2945606 0.74 RAB9A (0.77) TRPV1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL14864453 0.74 KMT2A (0.52) TRPV1RAB9ANPC1CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
EP-2323697-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY Siemens Medical Solutions USA, Inc. (US) 2011-05-25 EP disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB TRPV1 3331/4885MAP4K4 4649/4885CYP17A1 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.